Department of Anatomy, Cell Biology & Physiology, Indianapolis, IN, 46202, USA.
Indiana Center for Musculoskeletal Health, Indianapolis, IN, USA.
Curr Osteoporos Rep. 2024 Jun;22(3):318-329. doi: 10.1007/s11914-024-00872-4. Epub 2024 Apr 22.
The purpose of this review is to discuss the musculoskeletal consequences of cancer, including those that occur in the absence of bone metastases.
Cancer patients frequently develop cachexia, a debilitating condition reflected by weight loss and skeletal muscle wasting. The negative effects that tumors exert on bone health represents a growing interest amongst cachexia researchers. Recent clinical and pre-clinical evidence demonstrates cancer-induced bone loss, even in the absence of skeletal metastases. Together with muscle wasting, losses in bone demonstrates the impact of cancer on the musculoskeletal system. Identifying therapeutic targets that comprehensively protect musculoskeletal health is essential to improve the quality of life in cancer patients and survivors. IL-6, RANKL, PTHrP, sclerostin, and TGF-β superfamily members represent potential targets to counteract cachexia. However, more research is needed to determine the efficacy of these targets in protecting both skeletal muscle and bone.
本文讨论了癌症的肌肉骨骼并发症，包括那些在没有骨转移的情况下发生的并发症。
癌症患者经常出现恶病质，这是一种由体重减轻和骨骼肌消耗引起的衰弱状态。肿瘤对骨骼健康的负面影响引起了恶病质研究人员的关注。最近的临床和临床前证据表明，即使没有骨骼转移，癌症也会导致骨质流失。与肌肉消耗一起，骨质流失表明癌症对肌肉骨骼系统的影响。确定全面保护肌肉骨骼健康的治疗靶点对于提高癌症患者和幸存者的生活质量至关重要。IL-6、RANKL、PTHrP、硬化蛋白和 TGF-β 超家族成员是对抗恶病质的潜在靶点。然而，需要更多的研究来确定这些靶点在保护骨骼肌肉和骨骼方面的疗效。
